Clinical bottom line
Chronic cough is a prevalent and distressing symptom in patients with advanced respiratory diseases receiving palliative care. Effective management requires a multifaceted approach tailored to underlying pathophysiology, symptom severity, and patient preferences. Current evidence supports combining pharmacologic agents such as low-dose opioids with nonpharmacologic interventions including noninvasive respiratory therapies and symptom-focused supportive care. However, evidence remains limited by heterogeneous populations and variable outcome measures. Clinicians should adopt individualized, multidisciplinary strategies while recognizing the need for further research to optimize symptom control and quality of life.
What the evidence shows
Chronic cough in advanced respiratory disease often results from complex mechanisms including airway inflammation, mucus hypersecretion, and altered cough reflex sensitivity. It significantly impairs quality of life and may exacerbate breathlessness and fatigue (Bourke et al., 2012; Quibell et al., 2019).
Pharmacologic management primarily involves low-dose opioids such as morphine, which have demonstrated efficacy in reducing cough frequency and intensity by modulating central cough pathways, with acceptable safety profiles in palliative populations (Hakkak et al., 2024). Other agents, including neuromodulators and antitussives, have less robust evidence and require cautious use due to side effects and limited data.
Nonpharmacologic strategies play a crucial role. Noninvasive respiratory therapies, including humidified air, airway clearance techniques, and noninvasive ventilation, can alleviate cough by improving airway hydration and reducing respiratory muscle fatigue (Sumi et al., 2026). These interventions are particularly valuable in low-resource settings where pharmacologic options may be limited (Sooronbaev et al., 2016).
Integrated palliative care models emphasize multidisciplinary approaches combining symptom management, psychosocial support, and patient education to address cough and associated distress comprehensively (Huntley et al., 2020). Such models facilitate individualized care plans that align with patient goals and preferences.
Caveats and uncertainty
The evidence base for chronic cough management in advanced respiratory disease within palliative care is constrained by several factors. Many studies are observational or derived from heterogeneous patient populations with varying disease etiologies, limiting generalizability (Bourke et al., 2012). Randomized controlled trials specifically targeting cough outcomes in this setting are scarce.
Pharmacologic interventions, while promising, require careful titration to balance efficacy against adverse effects such as sedation and constipation. The long-term safety of opioids for cough suppression in non-malignant respiratory disease remains underexplored (Hakkak et al., 2024).
Nonpharmacologic therapies depend on patient tolerance and resource availability, which may vary widely across care settings. Evidence supporting their efficacy is often indirect or extrapolated from related respiratory conditions (Sumi et al., 2026; Sooronbaev et al., 2016).
Finally, patient-reported outcomes and quality-of-life measures are inconsistently reported, complicating assessment of intervention impact beyond cough frequency alone.
How this may change practice
Clinicians caring for patients with advanced respiratory disease should proactively assess chronic cough as a distinct symptom warranting targeted management. Incorporating low-dose opioids may be considered early for refractory cough, with vigilant monitoring for side effects.
Nonpharmacologic interventions, including airway clearance and noninvasive respiratory support, should be integrated into symptom management plans, especially when pharmacologic options are contraindicated or insufficient. Multidisciplinary collaboration involving respiratory therapists, palliative care specialists, and nursing staff can optimize individualized care.
In resource-limited environments, emphasis on accessible nonpharmacologic measures may improve symptom control and patient comfort (Sooronbaev et al., 2016). Clinicians should also engage patients and families in shared decision-making to align treatments with goals of care.
Ongoing research is needed to establish standardized protocols, validate outcome measures, and explore novel therapies for chronic cough in this population.